Exelixis thyroid cancer drug to get priority review; US decision in November
This article was originally published in Scrip
Executive Summary
Shares of Exelixis climbed as high as 8.6%, or 55 cents, on 30 July, after the company said the US FDA accepted the firm's new drug application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) – granting a six-month priority review.